Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Trial end date:
2021-07-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of EYP001a with respect to safety,
tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH